-
神仙打架!兩大乳腺癌ADC藥物頭對頭試驗結果出爐——LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY Breast 03 study.
-
不“看”PD-L1表達狀態,K藥聯合化療治療復發轉移性性宮頸癌PFS、OS雙贏——LBA2 Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Randomized, double-blind, phase III KEYNOTE-826 study.
-
高危Ⅱ期黑色素瘤輔助治療,K藥戰線再進一步——LBA3 Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase III trial.
以上精彩盡在:
– End –
加硒教授微信:623296388,送食療電子書,任選一本